Yonhap Infomax NewsSamsung Bioepis has signed a partnership with China's Frontline Biopharma to jointly develop, manufacture, and commercialize next-generation antibody-drug conjugates (ADCs), securing rights to two pipeline candidates and an exclusive license for one payload, with financial terms undisclosed.
#YonhapInfomax #SamsungBioepis #FrontlineBiopharma #AntibodyDrugConjugate #ADCPartnership #OncologyPipeline #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=86432
#YonhapInfomax #SamsungBioepis #FrontlineBiopharma #AntibodyDrugConjugate #ADCPartnership #OncologyPipeline #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=86432
Samsung Bioepis Signs ADC Drug Development Partnership with Chinese Biotech Firm
Samsung Bioepis has signed a partnership with China's Frontline Biopharma to jointly develop, manufacture, and commercialize next-generation antibody-drug conjugates (ADCs), securing rights to two pipeline candidates and an exclusive license for one payload, with financial terms undisclosed.